Meng Yang, Ying Meng, Hongwen Zhao, Li Huang, Xiaopeng Tang
Department of Nephrology, The First Affiliated Hospital of Army Medical University(Southwest Hospital), Chongqing, 400000, China.
Chongqing Maternal and Child Health Hospital, Chongqing, 400000, China.
BMC Pediatr. 2025 May 26;25(1):422. doi: 10.1186/s12887-025-05778-3.
We present a case of pediatric lupus nephritis (LN) with double positivity for BAFF and APRIL, highlighting the efficacy and safety of telitacicept in achieving complete remission. The patient, a 14-year-old Chinese male, presented with severe renal impairment and thrombotic microangiopathy (TMA). Conventional treatments were ineffective, and the patient experienced severe adverse reactions to rituximab. Subsequent treatment with telitacicept and sirolimus led to significant clinical improvement. After 6 months of follow-up, the patient achieved complete remission with an SLEDAI score of 0. This case underscores the potential of precision medicine in LN treatment. Individualized treatment based on pathological mechanisms is necessary, and telitacicept can improve the prognosis of lupus nephritis with good safety.
我们报告一例BAFF和APRIL双阳性的儿童狼疮性肾炎（LN）病例，突出了泰它西普在实现完全缓解方面的疗效和安全性。该患者为一名14岁中国男性，表现为严重肾功能损害和血栓性微血管病（TMA）。传统治疗无效，且患者对利妥昔单抗出现严重不良反应。随后使用泰它西普和西罗莫司治疗使临床症状显著改善。经过6个月随访，患者实现完全缓解，SLEDAI评分为0。该病例强调了精准医学在LN治疗中的潜力。基于病理机制的个体化治疗是必要的，且泰它西普可改善狼疮性肾炎的预后，安全性良好。
